K2M posted 2Q17 revenue of US $65.7MM, +10.9% vs. 2Q16, and 1H17 revenue of $127.6MM, +10.4% vs. 1H16. ORTHOWORLD estimates for segment growth follow.
2Q17
2Q16
$ Change
% Change
Spine
$63.4
$57.3
$6.1
10.7%
Orthobiologics
$2.3
$1.9
$0.3
18.1%
Total
$65.7
$59.2
$6.5
10.9%
1H17
1H16
$ Change
% Change
Spine
$123.3
$111.9
$11.4
10.2%
Orthobiologics
$4.3
$3.6
$0.6
17.7%
Total
$127.6
$115.5
$12.1
10.4%
2Q17 Geographic results: U.S. $50.7MM, +12.2%; ex-U.S. $14.9MM, +6.6%
Performance highlights:
Growth supported by new U.S. surgeon customers and new products, partially offset by decrease in existing customer sales and revenue in the U.K. and Ireland
Ex-U.S. growth supported by replenishment purchases in Italy and Saudi Arabia
Product launches included K2M’s first expandable interbody, the SAHARA® AL, and alpha launch of MOJAVE™ PL, the first 3D-printed expandable posterior lumbar interbody on the market (full launch slated for early 2018)
New partnerships included LifeHealthcare distribution agreement covering Australia and New Zealand, Japan Medicalnext for exclusive distribution in Japan
Received key Japan product registrations, including MESA® and EVEREST® lines
After close of quarter, announced exclusive license to a portfolio of 17 issued/pending patents for expandable interbody fusion devices, which will be developed using 3D printing
K2M posted 2Q17 revenue of US $65.7MM, +10.9% vs. 2Q16, and 1H17 revenue of $127.6MM, +10.4% vs. 1H16. ORTHOWORLD estimates for segment growth follow.
Q17 Q16 $ Change % Change
Spine $63.4 $57.3 ...
K2M posted 2Q17 revenue of US $65.7MM, +10.9% vs. 2Q16, and 1H17 revenue of $127.6MM, +10.4% vs. 1H16. ORTHOWORLD estimates for segment growth follow.
2Q17
2Q16
$ Change
% Change
Spine
$63.4
$57.3
$6.1
10.7%
Orthobiologics
$2.3
$1.9
$0.3
18.1%
Total
$65.7
$59.2
$6.5
10.9%
1H17
1H16
$ Change
% Change
Spine
$123.3
$111.9
$11.4
10.2%
Orthobiologics
$4.3
$3.6
$0.6
17.7%
Total
$127.6
$115.5
$12.1
10.4%
2Q17 Geographic results: U.S. $50.7MM, +12.2%; ex-U.S. $14.9MM, +6.6%
Performance highlights:
Growth supported by new U.S. surgeon customers and new products, partially offset by decrease in existing customer sales and revenue in the U.K. and Ireland
Ex-U.S. growth supported by replenishment purchases in Italy and Saudi Arabia
Product launches included K2M’s first expandable interbody, the SAHARA® AL, and alpha launch of MOJAVE™ PL, the first 3D-printed expandable posterior lumbar interbody on the market (full launch slated for early 2018)
New partnerships included LifeHealthcare distribution agreement covering Australia and New Zealand, Japan Medicalnext for exclusive distribution in Japan
Received key Japan product registrations, including MESA® and EVEREST® lines
After close of quarter, announced exclusive license to a portfolio of 17 issued/pending patents for expandable interbody fusion devices, which will be developed using 3D printing
Copy to clipboard 
